
1. j clin virol. 2008 aug;42(4):394-8. doi: 10.1016/j.jcv.2008.02.015. epub 2008 apr
29.

validation strategy hcv antibody testing two enzyme immunoassays in
a routine clinical laboratory.

vermeersch p(1), van ranst m, lagrou k.

author information: 
(1)department laboratory medicine, university leuven, leuven, belgium.
pieter.vermeersch@uz.kuleuven.be

background: centers disease control (cdc) guidelines require confirmation 
hepatitis c virus (hcv) screening-test-positive sera low signal/cut-off
(s/co) ratio recombinant immunoblot pcr. uk health protection agency
has suggested second enzyme immunoassay (eia) could used an
alternative confirmation non-immunocompromised patients.
objective: evaluate uk hpa approach 17,936 consecutive in-house sera
submitted hcv testing.
study design: axsym-positive sera (s/co> =1.0) tested monolisa plus.
axsym-positive sera patients confirmed pcr-positive considered 
hcv+. axsym-positive sera confirmed immunoblot according to
cdc guidelines.
results: 17,299 sera negative axsym. 637 axsym-positive sera,
384 patients confirmed pcr-positive. 250 sera, 120 were
negative immunoblot, 103 positive 30 indeterminate. 30
immunoblot-indeterminate sera pcr-negative. two patients monolisa plus+
and immunoblot- pcr-. one patient known immunoblot-, other
patient diagnosed non-a non-b hepatitis 1980s. nine sera from
hcv-positive patients monolisa plus-. two pcr- sera from
immunocompetent patients pcr- > =8 years six pcr- sera and
one pcr+ serum immunocompromised patients. sensitivity specificity 
of confirmation monolisa plus 98.15% 98.33% positive and
negative predictive values 99.58% 92.91% axsym-positive sera
(excluding immunoblot-indeterminate/pcr-negative sera). immunocompromised
patients false-negative excluded, sensitivity 99.58%.
conclusion: monolisa plus used alternative immunoblot the
confirmation axsym-positive sera.

doi: 10.1016/j.jcv.2008.02.015 
pmid: 18448386  [indexed medline]

